Skip to main content
SpringerLink
Log in

Regenerative Medicine at a Global Level: Current Patterns and Global Trends

  • Chapter
The Global Dynamics of Regenerative Medicine

Part of the book series: Health, Technology and Society ((HTE))

Abstract

Numerous claims have been made regarding the potential benefits that regenerative medicine will bring to clinical practice. However, robust data on what is happening in the field is difficult to secure. In this chapter we examine that data we have found to have a sufficient degree of accuracy in terms of global trends in three domains: corporate activity and interests; the sponsorship of clinical trials (CTs); and recent patent activity by firms and other organisations such as academic institutions and other ‘not-for-profit’ bodies. Such data is of interest in its own right because the domains chosen for investigation are important indicators of both the strength and the location (or ‘geographical shape’) of innovation in this emerging field. In addition, by focusing on these three domains the chapter contextualises the themes discussed and analysed in the chapters that follow.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Aldridge, S. (2010) Regenerative medicine: small steps towards the great leap forward, InPharm (16 August). Available at http://www.inpharm.com/news/regenerative-medicine-small-steps-towards-great-leap-forward

  • Appelbaum, F. R. (2007) Hematopoietic-Cell Transplantation at 50, New England Journal of Medicine, 357: 1472–1475.

    Article  Google Scholar 

  • Bergman, K. and G. Graff (2007a) The global stem cell patent landscape: implications for efficient technology transfer and commercial development, Nature Biotechnology, 25(4): 419–424.

    Article  Google Scholar 

  • Bergman, K. and G. Graff (2007b) Collaborative IP Management for Stem Cell Research and Development, Davis, CA: Centre for Intellectual Property Studies (CIP), Göteborg and Public Intellectual Property Resource for Agriculture (PIPRA).

    Google Scholar 

  • BIS (2011) Taking Stock of Regenerative Medicine in the United Kingdom, (July). UK Department of Business, Innovation and Skills (BIS) and UK Department of Health. Available at http://www.bis.gov.uk/assets/biscore/innovation/docs/t/11–1056-taking-stock-of-regenerative-medicine

    Google Scholar 

  • Blackburn-Starza, A. (2011) Ban on embryonic stem cell patents by European Court of Justice, BioNews, 630(24 October). Available at http://www.bionews.org.uk/page_109818.asp

  • Boseley, S. (2011) Geron abandons stem cell therapy as treatment for paralysis, The Guardian (15 November). Available at http://www.guardian.co.uk/science/2011/nov/15/geron-abandons-stem-cell-therapy

  • Brown, N. (2003) Hope against hype — accountability in biopasts, presents and futures, Science Studies, 16(2): 3–21.

    Google Scholar 

  • Brown, N. and M. Michael (2003) A sociology of expectations: retrospecting prospects and prospecting retrospects, Technology Analysis and Strategic Management, 15(1): 3–18.

    Article  Google Scholar 

  • Clancey, G. (2012) Intelligent island to biopolis: smart minds, sick bodies and millennial turns in Singapore, Science, Technology and Society, 17(1): 13–35.

    Article  Google Scholar 

  • Committee for Advanced Therapies and CAT Scientific Secretariat (2010) Use of unregulated stem-cell based medicinal products, The Lancet, 376 (14 August): 514.

    Article  Google Scholar 

  • Crunkhorn, S. (2012) Deal watch: shire increases focus on regenerative medicine, Nature Reviews Drug Discovery, 11: 430.

    Article  Google Scholar 

  • Cyranoski, D. (2012a) China’s stem-cell rules go unheeded, Nature, 484: 149–150.

    Article  Google Scholar 

  • Cyranoski, D. (2012b) Stem-cell therapy takes off in Texas, Nature, 483(1 March): 13–14.

    Article  Google Scholar 

  • Daar, A. S. and H. L. Greenwood (2007) A proposed definition of regenerative medicine, Journal of Tissue Engineering and Regenerative Medicine, 1(3): 179–84.

    Article  Google Scholar 

  • Datamonitor (2010) Pharmaceutical key trends 2010 — the patent cliff dominates but growth opportunities remain, DataMonitor 259(17 March).

    Google Scholar 

  • Deuten, J. J. and A. Rip (2000) Narrative infrastructure in product creation processes, Organization, 7(1): 69–83.

    Article  Google Scholar 

  • Dolgin, E. (2010) Survey details stem cell clinics ahead of regulatory approval, Nature Medicine, 16(5): 495.

    Article  Google Scholar 

  • Dunoon, A. and V. Vollebregt (2010) Can regenerative medicine save Big Pharma business model from the patent cliff?, Regenerative Medicine, 5(5): 687–690.

    Article  Google Scholar 

  • Dutton, G. (2012) Stem cell applications hasten into the clinic, Genetic Technology and Biotechnology News, 32(2) (January 15): 1–2.

    Article  Google Scholar 

  • European Court of Justice (2011a) A process which involves removal of a stem cell from a human embryo at the blastocyst stage, entailing the destruction of that embryo, cannot be patented. Press Release No 112/11, Luxembourg, 18 October 2011. Judgment in Case C-34/10 Oliver Brüstle v Greenpeace e.V. Available at http://curia.europa.eu/jcms/upload/docs/ application/pdf/2011–10/cp110112en.pdf

  • European Court of Justice (2011b) Judgment of the Court (Grand Chamber) of 18 October 2011. Oliver Brüstle v Greenpeace e V. Reference for a preliminary ruling: Bundesgerichtshof — Germany. Directive 98/44/EC — Article 6(2)(c) — Legal protection of biotechnological inventions. Available at http://curia.europa.eu/juris/liste.jsf?language=en&num=C-34/10

  • Friedman, Y. (2010) Location of pharmaceutical innovation: 2000–2009, Nature Reviews Drug Discovery, 9: 835.

    Article  Google Scholar 

  • Ginty, P. J., E. A. Rayment, P. Hourd, and D. J. Williams (2011) Regenerative medicine, resource and regulation: lessons learned from the remedi project, Regenerative Medicine, 6(2): 241–253.

    Article  Google Scholar 

  • Haseltine, W. A. (2001) The emergence of regenerative medicine: a new field and a new society, The Journal of Regenerative Medicine, 2: 17–23.

    Google Scholar 

  • Hogarth, S. and B. Salter (2010) Regenerative medicine in Europe: global competition and innovation governance, Regenerative Medicine, 5(6): 971–985.

    Article  Google Scholar 

  • Hopkins, M., S. Mahdi, S. M. Thomas and P. Patel (2006) The Patenting of Human DNA: Global Trends in Public and Private Sector Activity (The PATGEN Project). Sussex: Science and Technology Policy Research Unit (SPRU).

    Google Scholar 

  • Kemp, P. (2006) History of regenerative medicine: looking backwards to move forwards, Regenerative Medicine, 1(5): 653–669.

    Article  Google Scholar 

  • Light, D. W. (2009) Global drug discovery: Europe is ahead, Health Affairs, 28: 969–977.

    Article  Google Scholar 

  • Lindvall, O. and I. Hyun (2009) Medical Innovation Versus Stem Cell Tourism, Science 324(5935): 1664–1665.

    Article  Google Scholar 

  • Lysaght, M. J., A. Jaklenec and E. Deweerd (2008) Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics, Tissue Engineering: Part A, 14(2): 305–315.

    Article  Google Scholar 

  • Martin, P. et al. (2006) Commercial development of stem cell technology: lessons from the past, strategies for the future, Regenerative Medicine, 1(6): 801–807.

    Article  Google Scholar 

  • Martin, P. et al. (2008) Capitalizing hope: the commercial development of umbilical cord blood stem cell banking, New Genetics and Society, 27(2): 127–143.

    Article  Google Scholar 

  • Martino, M. (2010) Gene therapy rises from the dead, FierceBiotech (23 April). Available at www.fiercebiotech.com/story/gene-therapy-rises-dead/2010–04–23?utm medium=nl&utm source=internal#ixzz1HRiAK3EG

  • Mason, C. (2007) Regenerative medicine 2.0, Regenerative Medicine, 2(1): 11–18.

    Article  Google Scholar 

  • Mason, C. and P. Dunnill (2008a) The strong financial case for regenerative medicine and the regen industry, Regenerative Medicine, 3(3): 351–363.

    Article  Google Scholar 

  • Mason, C. and P. Dunnill (2008b) A brief definition of regenerative medicine, Regenerative Medicine, 3(1): 1–5.

    Article  Google Scholar 

  • McCann, S. R. (2003) The history of bone marrow transplantation, in N. S. Hakim and V. E. Papalois (eds) Organ and Cell Transplantation. London: Imperial College Press.

    Google Scholar 

  • McKernan, R. et al. (2010) Pharma’s developing interest in stem cells, Cell Stem Cell, 6: 517–520.

    Article  Google Scholar 

  • Melnikova, I. (2012) Rare diseases and orphan drugs, Nature Reviews Drug Discovery, 11: 267–268.

    Article  Google Scholar 

  • Morrison, M. (2012) Promissory futures and possible pasts: the dynamics of contemporary expectations in regenerative medicine, BioSocieties, 7: 3–22.

    Article  Google Scholar 

  • MRC (2012) A Strategy for UK Regenerative Medicine. Document prepared by the UK Medical Research Council (MRC) in partnership with the BBSRC, EPSRC, ESRC and the Technology Strategy Board (TSB) (April).

    Google Scholar 

  • Neish, J. (2007) Stem cells as screening tools in drug discovery, Current Opinion in Pharmacology, 7(5): 515–520.

    Article  Google Scholar 

  • Nelson, J. (1998) Analysis of patenting within gene therapy, Expert Opinion on Therapeutic Patents, 8(11): 1495–1505.

    Article  Google Scholar 

  • Oldham, P. and A.M. Cutter (2006) Mapping global status and trends in patent activity for biological and genetic material, Genomics, Society and Policy, 2(2): 62–91.

    Google Scholar 

  • Philippidis, A. (2011) Orphan drugs, big pharma, Human Genetics Therapy, 22: 1037–1040.

    Article  Google Scholar 

  • Plagnol, A. C., E. Rowley, P. Martin and F. Livesey (2009) Industry perceptions of barriers to commercialization of regenerative medicine products in the UK, Regenerative Medicine, 4(4): 549–559.

    Article  Google Scholar 

  • Reiss, T. and E. Strauss (1998) Gene therapy — the dynamics of patenting worldwide, Expert Opinion on Therapeutic Patents, 8(2): 173–179.

    Article  Google Scholar 

  • Ryan, K. A. et al. (2010) Tracking the rise of stem cell tourism, Regenerative Medicine, 5: 27–33.

    Article  Google Scholar 

  • Suarez-Villa, L. (2000) Invention and the Rise of Technocapitalism. Boston, MAUS and Oxford, UK: Rowman & Littlefield.

    Google Scholar 

  • Takahashi, K. et al. (2001) Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131(5): 861–872.

    Article  Google Scholar 

  • Thomson, J. A. et al. (1998) Embryonic stem cell lines derived from human blastocysts, Science, 282: 1145–1147.

    Article  Google Scholar 

  • US Department of Commerce (2010) US Patent and Trademark Office. Manual of Patent Examining Procedure. Virginia: US Patent and Trademark Office.

    Google Scholar 

  • Wainwright, S. et al. (2008) Shifting paradigms? Reflections on regenerative medicine, embryonic stem cells and pharmaceuticals, Sociology of Health and Illness, 30(6): 959–974.

    Article  Google Scholar 

  • Waters, R (2010) Gene Therapy revival spurs hope for Genzyme, Pfizer, Bloomberg Business Week (26 April). http://www.bloomberg.com/news/2010–04–22/-dead-as-doornail-gene-therapy-revival-spurs-hope-for-genzyme-pfizer.html

  • Webster, A. (2013) Introduction: the boundaries and mobilities of regenerative medicine, in A. Webster (ed) The Global Dynamics of Regenerative Medicine: A Social Science Critique. Basingstoke: Palgrave Macmillan.

    Chapter  Google Scholar 

  • Webster, A. et al. (2011) Regenerative medicine in Europe: emerging needs and challenges in a global context (REMEDiE), Final Report to the European Cornmission, SATSU, University of York. Available at http://www.york.ac.uk/satsu/remedie.reports

    Google Scholar 

  • Whitaker, M. and L. Foley (2011) What are the challenges of bringing RM to the clinic? Paper presented at 3rd REMEDiE conference, Bilbao, Spain, 10 April. Available at http://www.york.ac.uk/satsu/remedie

    Google Scholar 

  • Yamanaka, S. (2009) A fresh look at iPS cells, Cell, 137(April 3): 13–17.

    Article  Google Scholar 

Download references

Authors
  1. Graham Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of York, UK

    Andrew Webster

Copyright information

© 2013 Graham Lewis

About this chapter

Cite this chapter

Lewis, G. (2013). Regenerative Medicine at a Global Level: Current Patterns and Global Trends. In: Webster, A. (eds) The Global Dynamics of Regenerative Medicine. Health, Technology and Society. Palgrave Macmillan, London. https://doi.org/10.1057/9781137026552_2

Download citation

Publish with us

Policies and ethics

Search

Navigation